We are live on ! Find out more
BCDA icon

BioCardia
BCDA

24 hedge funds and large institutions have $5.49M invested in BioCardia in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

4% more funds holding

Funds holding: 23 → 24 (+1)

0.13% less ownership

Funds ownership: 1.18% → 1.05% (-0.13%)

5% less capital invested

Capital invested by funds: $5.78M → $5.49M (-$292K)

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

55% less call options, than puts

Call options by funds: $87K | Put options by funds: $195K

Holders
24
Holders Change
+1
Holders Change %
+4.35%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
6
Closed
4
Calls
$87K
Puts
$195K
Net Calls
-$108K
Net Calls Change
-$66K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$472K
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$54.3K
3
Renaissance Technologies
Renaissance Technologies
New York
+$27.1K
4
LPL Financial
LPL Financial
California
+$21.9K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$21.2K

Top Sellers

Rank Fund Capital Flow
1
RAM
Roumell Asset Management
Maryland
-$796K
2
FM
Family Management
New York
-$276K
3
VF
Virtu Financial
New York
-$109K
4
TSS
Two Sigma Securities
New York
-$41K
5
Citadel Advisors
Citadel Advisors
Florida
-$16.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
TSS
26
Two Sigma Securities
New York
– -$41K -1,413 Closed
TRCT
27
Tower Research Capital (TRC)
New York
– -$4K -147 Closed
1
2

BCDA Hedge Fund Activity: Q1 2022 in Review

24 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in BioCardia (BCDA) for Q1 2022, worth a combined $5.49M — down 5.1% from $5.78M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new BCDA positions and 4 closed out — a net gain of 1 holder — while 4 added to existing stakes and 6 trimmed.

The largest buyer was Vanguard Group, adding an estimated $472K. The largest seller was Roumell Asset Management, cutting an estimated $796K.

  • 24 institutional investors held BioCardia (BCDA) as of Q1 2022, up from 23 in Q4 2021.
  • Funds reported $5.49M of BioCardia stock for Q1 2022, down 5.1% quarter-over-quarter.
  • 5 funds opened new BioCardia positions in Q1 2022 and 4 closed out, a net change of +1 holder.
  • The largest BioCardia buyer in Q1 2022 was Vanguard Group, an estimated $472K added.
  • The largest BioCardia seller in Q1 2022 was Roumell Asset Management, an estimated $796K sold.

Based on aggregated 13F filings for Q1 2022.